Patents by Inventor Marvin Gee

Marvin Gee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230287346
    Abstract: Provided are methods for isolating T-cells with T cell receptors (TCRs) optimized for reactivity to specific peptides and decreased cross-reactivity to non-target peptides. Advantageously, TCRs of the invention can be optimized to target cancer antigens and peptides while having reducing reactivity to healthy cells. Methods of the invention utilize a novel combination of culturing conditions that increase T-cell activation and allow for validation of TCR activity. Culturing conditions of the invention further reduce culturing times generally needed to achieve expanded reactive T-cells. Because of the robust nature of the activation and validation conditions of the present invention, variants of identified TCRs can also be optimized and validated for their response to peptides, including cancer peptides.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 14, 2023
    Inventors: Leah Sibener, John Leonard, Alejandro Ramirez, Marvin Gee
  • Publication number: 20230287448
    Abstract: Provided are methods for isolating T-cells with T cell receptors (TCRs) optimized for reactivity to specific peptides and decreased cross-reactivity to non-target peptides. Advantageously, TCRs of the invention can be optimized to target cancer antigens and peptides while having reducing reactivity to healthy cells. Methods of the invention utilize a novel combination of culturing conditions that increase T-cell activation and allow for validation of TCR activity. Culturing conditions of the invention further reduce culturing times generally needed to achieve expanded reactive T-cells. Because of the robust nature of the activation and validation conditions of the present invention, variants of identified TCRs can also be optimized and validated for their response to peptides, including cancer peptides.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 14, 2023
    Inventors: Leah Sibener, John Leonard, Marvin Gee, James Byers
  • Publication number: 20230288400
    Abstract: Provided are methods for isolating T-cells with T cell receptors (TCRs) optimized for reactivity to specific peptides and decreased cross-reactivity to non-target peptides. Advantageously, TCRs of the invention can be optimized to target cancer antigens and peptides while having reducing reactivity to healthy cells. Methods of the invention utilize a novel combination of culturing conditions that increase T-cell activation and allow for validation of TCR activity. Culturing conditions of the invention further reduce culturing times generally needed to achieve expanded reactive T-cells. Because of the robust nature of the activation and validation conditions of the present invention, variants of identified TCRs can also be optimized and validated for their response to peptides, including cancer peptides.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 14, 2023
    Inventors: Leah Sibener, Alejandro Ramirez, John Leonard, Marvin Gee, David Victor Liu
  • Publication number: 20230288405
    Abstract: Provided are methods for isolating T-cells with T cell receptors (TCRs) optimized for reactivity to specific peptides and decreased cross-reactivity to non-target peptides. Advantageously, TCRs of the invention can be optimized to target cancer antigens and peptides while having reducing reactivity to healthy cells. Methods of the invention utilize a novel combination of culturing conditions that increase T-cell activation and allow for validation of TCR activity. Culturing conditions of the invention further reduce culturing times generally needed to achieve expanded reactive T-cells. Because of the robust nature of the activation and validation conditions of the present invention, variants of identified TCRs can also be optimized and validated for their response to peptides, including cancer peptides.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 14, 2023
    Inventors: Leah Sibener, Alejandro Ramirez, John Leonard, Marvin Gee, David Victor Liu
  • Publication number: 20230287080
    Abstract: Provided are methods for isolating T-cells with T cell receptors (TCRs) optimized for reactivity to specific peptides and decreased cross-reactivity to non-target peptides. Advantageously, TCRs of the invention can be optimized to target cancer antigens and peptides while having reducing reactivity to healthy cells. Methods of the invention utilize a novel combination of culturing conditions that increase T-cell activation and allow for validation of TCR activity. Culturing conditions of the invention further reduce culturing times generally needed to achieve expanded reactive T-cells. Because of the robust nature of the activation and validation conditions of the present invention, variants of identified TCRs can also be optimized and validated for their response to peptides, including cancer peptides.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 14, 2023
    Inventors: Leah Sibener, John Leonard, Marvin Gee
  • Publication number: 20230227780
    Abstract: Provided are methods for isolating T-cells with T cell receptors (TCRs) optimized for reactivity to specific peptides and decreased cross-reactivity to non-target peptides. Advantageously, TCRs of the invention can be optimized to target cancer antigens and peptides while having reducing reactivity to healthy cells. Methods of the invention utilize a novel combination of culturing conditions that increase T-cell activation and allow for validation of TCR activity. Culturing conditions of the invention further reduce culturing times generally needed to achieve expanded reactive T-cells. Because of the robust nature of the activation and validation conditions of the present invention, variants of identified TCRs can also be optimized and validated for their response to peptides, including cancer peptides.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 20, 2023
    Inventors: Leah Sibener, John Leonard, Marvin Gee
  • Publication number: 20210309993
    Abstract: Described herein is an antigen screening library comprising a plurality of Human Leukocyte Antigen (HLA)-antigen polypeptide complexes, the HLA-antigen polypeptide complexes comprising: (a) an HLA polypeptide; (b) a randomized antigen polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 209, wherein the randomized antigen polypeptide is selected to specifically bind to peptide binding cleft of the HLA polypeptide; and (c) a ?2 microglobulin polypeptide. These libraries can be used to determine antigenic polypeptides capable of interacting and stimulating a selected T cell receptor (TCR).
    Type: Application
    Filed: August 30, 2019
    Publication date: October 7, 2021
    Applicant: 3T BIOSCIENCES, INC.
    Inventors: MARVIN GEE, LEAH SIBENER
  • Publication number: 20200392201
    Abstract: Compositions and methods are provided for peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
    Type: Application
    Filed: August 3, 2020
    Publication date: December 17, 2020
    Inventors: MARVIN GEE, MARK M. DAVIS, ARNOLD HAN, KENAN CHRISTOPHER GARCIA
  • Publication number: 20200010527
    Abstract: Compositions and methods are provided for peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
    Type: Application
    Filed: March 21, 2018
    Publication date: January 9, 2020
    Inventors: Marvin Gee, Mark M. Davis, Arnold Han, Kenan Christopher Garcia